Top 10 Patent Cliffs of 2017

Patent expiration is clearing a path for generics to take over; here’s a look at the top 10 patents expiring this year.

Patent File / Image: FiercePharma
Patent File / Image: FiercePharma

A February 21st FiercePharma article examined upcoming patent cliffs that will level the playing field for generics rivals. Because the exact date a drug loses market exclusivity is never guaranteed due to add-on patents and legal settlements, the list is comprised of drugs that will lose patent protection in 2017 and drugs that will become vulnerable to generics and biosimilars. See the source article for more info, here’s the list along with 2016 sales:

1. Teva’s Copaxone - $3.48 billion

2. Eli Lilly’s Cialis - $1.42 billion

3. Pfizer’s Viagra - $1.15 billion

4. Takeda’s Velcade - $1.13 billion

5. Bristol-Myers’ Sustiva - $901 million

6. Novartis’ Sandostatin - $853 million

7. Novo Nordisk’s Norditropin SimpleXx - $642.5 million

8. Gilead’s Viread - NA

9. Pfizer’s Pristiq - NA

10. Eli Lilly’s Strattera - $535 million

Special Report: Track & Trace
Discover new tools to approach the supply chain that allow you to leverage your data, see real-time visibility, and forecast future sales. You’ll also learn about KH Hive, an in-house digital demand planning tool that Kraft Heinz created to help the company realize its goals, forecasting sales expectation down to the SKU level, location level, and daily level.
Read More
Special Report: Track & Trace
Rethinking Packaging Robotics to Prioritize Flexibility
In this eBook, you’ll learn how to guard against the traps that CPGs sometimes inadvertently set for themselves when implementing robotics that lead to automation “brittleness.”
Read More
Rethinking Packaging Robotics to Prioritize Flexibility